About this Research Topic
We are organizing a series of five articles in the Neuro-Oncology section of Frontiers in Oncology on the topic of "Advances in Diffuse Intrinsic Pontine Glioma (DIPG)".
Rationale:
In the past three decades, despite improvements in chemotherapy and radiation delivery techniques, there have been no significant advances in the treatment or prognosis of children with a diffuse intrinsic pontine glioma (DIPG). In the past few years, through evaluation of biopsy and/or autopsy tumor tissue specimens at a few leading research institutions, and with the advent of next generation sequencing and other high throughput "omics" platforms, there are exciting new discoveries in DIPG tumor genetics and epigenetics that signal a new era in the diagnosis, development of preclinical models and design of clinical trials for this challenging brain tumor.
Tentative titles and authors are:
1. DIPG in children - what can we learn from the past? (Dr. M. Vanan, CancerCare Manitoba, Winnipeg, Canada; Dr. D. Eisenstat, Stollery Children's Hospital, University of Alberta, Edmonton, Canada).
2. Pathology and Molecular Genetics and Epigenetics of DIPG (Dr. C. Hawkins, The Hospital for Sick Children, Toronto, Canada).
3. Animal and Other Preclinical Models of DIPG (Dr. O. Becher, Duke University Medical Center, Durham NC, USA).
4. Future clinical trials in DIPG: bringing epigenetics to the clinic (Dr. M. Kieran, Dana Farber Cancer Institute, Boston MA, USA).
5. DIPG in adults - a time of opportunity (Dr. D. Reardon, Dana Farber Cancer Institute, Boston MA, USA).
Rationale:
In the past three decades, despite improvements in chemotherapy and radiation delivery techniques, there have been no significant advances in the treatment or prognosis of children with a diffuse intrinsic pontine glioma (DIPG). In the past few years, through evaluation of biopsy and/or autopsy tumor tissue specimens at a few leading research institutions, and with the advent of next generation sequencing and other high throughput "omics" platforms, there are exciting new discoveries in DIPG tumor genetics and epigenetics that signal a new era in the diagnosis, development of preclinical models and design of clinical trials for this challenging brain tumor.
Tentative titles and authors are:
1. DIPG in children - what can we learn from the past? (Dr. M. Vanan, CancerCare Manitoba, Winnipeg, Canada; Dr. D. Eisenstat, Stollery Children's Hospital, University of Alberta, Edmonton, Canada).
2. Pathology and Molecular Genetics and Epigenetics of DIPG (Dr. C. Hawkins, The Hospital for Sick Children, Toronto, Canada).
3. Animal and Other Preclinical Models of DIPG (Dr. O. Becher, Duke University Medical Center, Durham NC, USA).
4. Future clinical trials in DIPG: bringing epigenetics to the clinic (Dr. M. Kieran, Dana Farber Cancer Institute, Boston MA, USA).
5. DIPG in adults - a time of opportunity (Dr. D. Reardon, Dana Farber Cancer Institute, Boston MA, USA).
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
